Core Insights - The article discusses the completion and operational readiness of Hubei Weiqi's green intelligent manufacturing project for producing 30,000 tons of biodegradable PHA materials annually, with the first phase achieving a production capacity of 10,000 tons [1][2][3] Project Overview - Project Name: Annual production of 30,000 tons of synthetic biological PHA biodegradable materials green intelligent manufacturing project (Phase I) [3] - Construction Unit: Hubei Weiqi Biotechnology Co., Ltd. [3] - Location: Yichang City, Xiaoting District, within the Anqi Biotechnology Park [3] - Nature of Construction: New construction [3] - Total Investment for Phase I: 34 million yuan [3] - Project Area: Approximately 200.86 acres with a total building area of about 34,516 square meters [3] Production Details - Phase I includes the construction of a production facility for 10,000 tons of PHA, along with supporting facilities such as drying workshops and fermentation and extraction workshops [1] - The products produced in Phase I include PHB and P34HB, with a production ratio of approximately 1:2 for PHB and 3,4-HB [1] - Finished products are packaged in various sizes, including 20 kg, 40 kg, 600 kg, and ton bags for sale [1] Environmental Compliance - The project has completed trial operations and has met the designed production capacity, with all environmental protection facilities for wastewater, waste gas, and noise having been tested and functioning properly [2]

Core Insights - The Fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) was held in Ningbo, featuring over 60 experts and executives sharing more than 40 presentations on various topics related to bio-manufacturing and green chemistry [2][4]. Group 1: Conference Overview - The conference included four main sessions: macro forum on bio-manufacturing, green chemistry and new materials, AI applications in bio-manufacturing, and future food & agriculture [2]. - Additional activities included a youth forum, high-level discussions on bio-manufacturing, and a closed-door seminar on the "2025 AI Empowering Bio-Manufacturing Industry Innovation Development Blue Book" [2]. Group 2: Keynote Highlights - Zhang Xian'en, Dean of the Synthetic Biology Institute at Shenzhen University, emphasized the rapid development of synthetic biology over the past decade, highlighting AI's role in overcoming the complexity of biological systems [10][11]. - Chen Luoping, Director of the Electronic Information Research Institute, noted that AI in bio-manufacturing presents opportunities for significant advancements, particularly in enzyme design and strain construction, despite existing challenges such as data scarcity and algorithm limitations [12][13]. Group 3: Technological Innovations - Chen Haibin, Vice President of Ningbo Enzyme Bioengineering Co., discussed the company's transition from technological innovation to product innovation, achieving industrial-scale production of small organic acids and bio-based nylon [15]. - Feng Yan, a professor at Shanghai Jiao Tong University, presented breakthroughs in enzyme molecular design and gene editing, which enhance the bio-synthesis of high-value compounds [19]. Group 4: Green Chemistry and New Materials - Wang Dan from Chongqing University addressed the bottlenecks in bio-synthesis of polyamide materials and shared advancements in developing key monomers for industrial applications [23]. - Li Zhen, co-founder of Suzhou Polygen Biotech, highlighted the company's use of straw as a raw material for producing bio-based succinic acid at a scale that is cost-competitive with petrochemical products [28]. Group 5: Industry Collaboration and Future Directions - The conference featured a signing ceremony for a joint laboratory between Shenzhen University and Ningbo Enzyme Bioengineering Co., aimed at fostering collaboration in synthetic biology research [6]. - The high-level discussions focused on the future trends of bio-manufacturing, technological innovation, and industry chain collaboration, aiming for high-quality development in the synthetic biology sector [56].

工业和信息化部新闻宣传中心主任张学军在发布会上表示，近年来，伴随生物制造领域科技创新的加速 突破、政策体系的逐步完善、产业要素的持续投入，我国生物制造发展跑出"加速度"，原创性研究成果 不断涌现、成果产业化步伐持续加快、代表性行业企业竞相发展，生物制造领域的科技创新对新产业 （300832）、新模式、新动能的催生带动作用显著增强。在此背景下，本次论坛以"生机无限制引未 来"为主题，以"推动生物制造领域科技创新和产业创新融合发展"为宗旨，内容丰富，亮点纷呈：设定 了"1+3+N"的活动架构，包含1场开幕式暨主论坛，3场平行会议，N项特色活动。其中，开幕式暨主论 坛将围绕"科技创新引领现代化产业体系建设"目标，邀请一批顶尖学者和创新企业家分享真知灼见，发 布一批生物制造领域创新发展的最新成果，展示一批行业各方的创新实践和成功经验；平行会议方面， 面向生物制造领域科技创新和产业创新融合发展的三个重点方向，将策划举办合成生物学技术创新会 议、生物制造产业转化促进会议以及新兴技术赋能合成生物学创新会议；特色活动方面，本次论坛将突 出科技创新引领、助力产业宣传普及、展现常德地方产业特色，推出生物制造领域颠覆性创新成果、成 ...

Core Viewpoint - The 2025 China Biomanufacturing Technology Innovation Forum aims to promote the integration of technological and industrial innovation in the biomanufacturing sector, highlighting its potential to lead the Fourth Industrial Revolution and transform traditional manufacturing and agriculture [1][3]. Group 1: Forum Overview - The forum will take place from September 25 in Changde, Hunan, lasting for two days, with the theme "Unlimited Vitality Leads the Future" [1]. - The event is structured around "1+3+N," which includes one opening ceremony and main forum, three parallel sessions, and multiple special activities [3]. Group 2: Key Activities - The main forum will focus on "Technological Innovation Leading the Construction of a Modern Industrial System," featuring top scholars and innovative entrepreneurs sharing insights and showcasing the latest achievements in biomanufacturing [3]. - Parallel sessions will cover three key areas: synthetic biology technology innovation, biomanufacturing industry transformation, and the integration of emerging technologies like AI with biomanufacturing [3]. Group 3: Special Activities - The forum will highlight disruptive innovations in biomanufacturing and share successful case studies, along with a "Biomanufacturing Industry Science Popularization Report" to enhance public understanding [4]. - Special activities will also include showcasing Changde's local industrial capabilities and inviting investment in biomanufacturing [4]. Group 4: Changde's Biomanufacturing Landscape - Changde has a solid foundation in biomanufacturing, with a mature innovation chain and significant policy support, making it a reference point for innovation exploration [5]. - The synthetic biomanufacturing industry in Changde has seen a remarkable growth rate of 23.5% from January to July this year [5]. - A new local regulation to promote the development of the synthetic biomanufacturing industry was approved, marking a significant step in institutionalizing policy benefits [5].

新京报贝壳财经讯（记者陈维城）8月21日，记者在2025中国生物制造科技创新论坛新闻发布会上获 悉，本次论坛以"生机无限 制引未来"为主题，将于9月25日在湖南常德正式开幕，论坛为期2天，将探 讨合成生物与生物制造领域研究的最新进展，分享生物制造前沿成果，探讨加快科技成果转化的实现路 径。 工业和信息化部新闻宣传中心主任张学军表示，近年来，伴随生物制造领域科技创新的加速突破、政策 体系的逐步完善、产业要素的持续投入，我国生物制造发展跑出"加速度"，原创性研究成果不断涌现、 成果产业化步伐持续加快、代表性行业企业竞相发展，生物制造领域的科技创新对新产业（300832）、 新模式、新动能的催生带动作用显著增强。 清华大学合成与系统生物学中心秘书长吴赴清提到，生物制造是科技创新和产业创新融合发展的重要领 域，具备引领第四次工业革命的潜力，将会带来重构传统制造业的生产模式、替代传统天然产物的获取 方式、颠覆传统农业的种养殖模式等一系列重大变革。 据悉，本次论坛设定了"1+3+N"的活动架构，包含1场开幕式暨主论坛，3场平行会议，N项特色活动。 开幕式暨主论坛将围绕"科技创新引领现代化产业体系建设"目标，发布一批生物制 ...

平行会议方面，面向生物制造领域科技创新和产业创新融合发展的三个重点方向，策划举办合成生物学技术创新会议，邀请生 物制造领域专家学者等围绕行业创新趋势热点进行分享交流；策划举办生物制造产业转化促进会议，邀请创新企业家、科技服 务业机构代表等围绕生物制造领域产业成果转化路径、所需平台要素等进行交流对接；策划举办新兴技术赋能合成生物学创新 会议，邀请人工智能、智能制造等领域专家及企业家分享探讨人工智能等新兴技术与生物制造融合发展的新场景、新模式、新 方向。 21世纪经济报道见习记者冉黎黎 北京报道 2025年政府工作报告提出，建立未来产业投入增长机制，培育生物制造等未来产业。8月21日，2025中国生物制造科技创新论坛 新闻发布会召开，发布会上介绍，2025中国生物制造科技创新论坛将于9月25日在湖南常德正式开幕，为期2天，论坛主题为"生 机无限 制引未来"。论坛以"推动生物制造领域科技创新和产业创新融合发展"为宗旨，设定了"1+3+N"的活动架构，包含1场开 幕式暨主论坛，3场平行会议，N项特色活动。 "生物制造是科技创新和产业创新融合发展的重要领域，具备引领第四次工业革命的潜力，将会带来重构传统制造业的生产模 ...

Core Viewpoint - The Ministry of Industry and Information Technology of China has announced the first batch of iconic biomanufacturing products, including 36 items, with Jia Bi You Biotechnology's 2'-fucosyllactose (2'-FL) recognized for its biomanufacturing capabilities [1][2]. Group 1: Biomanufacturing Product Recognition - The selection of iconic biomanufacturing products aims to promote original and disruptive technological advancements in the biomanufacturing sector, accelerating the transformation of innovative results into productive capabilities [2]. - 2'-FL is a human milk oligosaccharide (HMO) that is the most abundant in breast milk, known for its physiological activities that support the development of newborns' gut and immune systems [2]. Group 2: Jia Bi You's Technological Advancements - Jia Bi You is one of the earliest companies in China to focus on HMO research, initiating its synthetic biology project for HMOs in 2012 [5]. - The company employs advanced techniques such as metabolic engineering and integrated engineering technologies to enhance the industrialization of HMOs, achieving high production efficiency and product purity [5]. Group 3: Production and Market Potential - By the end of 2023, Jia Bi You's HMOs products have passed biosafety reviews, with 2'-FL approved as a food nutrition enhancer and production licenses obtained [6]. - The company has achieved high production levels for several HMOs, with 2'-FL, 3-FL, and LNT reaching international advanced levels, while 3'-SL, 6'-SL, and LNnT meet domestic advanced standards [6]. - The market for HMOs is expected to expand due to increasing consumer demand for health foods and advancements in HMO industrialization technology, driving upgrades in infant formula, adult nutrition, and functional foods [6]. Group 4: Future Collaborations and Innovations - Jia Bi You plans to collaborate with well-known dairy companies and continue market development in regions where HMO regulations have been established [7]. - The company is set to open a new research and innovation center in Wuhan in 2025, focusing on synthetic biology and integrating cutting-edge technologies to create a comprehensive biomanufacturing ecosystem [7]. - The promotion of the first batch of iconic biomanufacturing products is expected to stimulate innovation in China's biomanufacturing sector, contributing to high-quality industry development and enhancing China's global position in biomanufacturing [7].

Group 1 - The Ministry of Industry and Information Technology and the National Health Commission of China have launched a notice to collect innovative applications of biological manufacturing technologies in the food processing sector, focusing on areas such as food raw materials, food additives, and food and beverage manufacturing [1] - The application directions should align with the goal of building a diversified food supply system and have significant promotional value for industry development, referencing safety evaluation requirements for genetically modified microorganisms [1] - Specific conditions for the applications include: products must be developed domestically and have entered small-scale trial production or mass production; products must have sufficient research results proving their safety or have been approved in other countries for food processing; and products must meet the criteria for "three new foods" in China but have not yet been approved [1] Group 2 - Huazhong Securities has released a research report indicating that frontier research in life sciences remains active, with a global biotechnology revolution accelerating its integration into economic and social development, providing new solutions for major challenges such as health, climate change, resource security, and food security [2] - The report suggests that the biological economy is emerging as a trillion-dollar sector, highlighting the potential for significant investment opportunities in this field [2]

Core Viewpoint - The report highlights the financial performance and operational developments of Cabio Biotech (Wuhan) Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and profit, alongside advancements in product offerings and market expansion strategies [1][3]. Company Overview and Financial Indicators - Cabio Biotech is a leading player in the synthetic biology sector, focusing on high-quality nutrient products and innovative solutions for the global nutrition and health market [4]. - The company reported a revenue of approximately 306.73 million yuan, representing a 17.60% increase compared to the same period last year [3]. - The total profit reached approximately 123.16 million yuan, marking a 57.82% increase year-on-year [3]. - The net profit attributable to shareholders was approximately 107.95 million yuan, up 59.01% from the previous year [3]. - The company's total assets increased by 12.31% to approximately 1.84 billion yuan, while net assets rose by 7.64% to approximately 1.63 billion yuan [3]. Main Business and Industry Situation - The company utilizes synthetic biology as a foundational technology to produce essential fatty acids and other bioactive compounds, which are widely used in infant formula, health foods, and personal care products [4][6]. - Key products include ARA (Arachidonic Acid), DHA (Docosahexaenoic Acid), and various oligosaccharides, which are essential for infant development and health [4][6]. - The company has established three production bases that meet international standards and has a comprehensive supply chain covering over 30 countries [4][6]. Market Trends and Opportunities - The Chinese government has implemented policies to encourage childbirth, which is expected to boost the maternal and infant consumption market, positively impacting the demand for ARA and DHA products [7]. - The global Omega-3 market is projected to grow significantly, with a focus on high-purity DHA products, driven by increasing health awareness and aging populations [8][10]. - The company is positioned to benefit from the growing trend of replacing fish oil with algae-derived DHA in various applications, including functional foods and clinical nutrition [10][11]. Technological Advancements and Competitive Edge - Cabio Biotech has developed a robust technological platform that integrates various capabilities in synthetic biology, enhancing its product development and production efficiency [14][16]. - The company has achieved several certifications, including FDA GRAS and EU Novel Food, ensuring the quality and safety of its products [15][16]. - Continuous investment in automation and smart manufacturing systems has improved production efficiency and product quality, solidifying the company's competitive position in the market [16][17].

Core Viewpoint - The article highlights the significant growth and innovation in the bio-based technology sector, particularly focusing on the achievements of Kasei Biotech in the production of bio-based materials and their applications in various industries [4][6]. Group 1: Financial Performance - Kasei Biotech reported a revenue of 1.671 billion yuan for the first half of 2025, marking a year-on-year increase of 15.68% [4]. - The net profit attributable to shareholders reached 309 million yuan, reflecting a year-on-year growth of 24.74% [4]. - The company's non-recurring net profit was 296 million yuan, up 23.67% year-on-year, achieving a historical high in revenue [4]. Group 2: Product Development and Market Position - Kasei Biotech maintains a leading global position in the production of long-chain dicarboxylic acids (DC10-DC18), with a production capacity of 115,000 tons and record sales [6]. - The bio-based dicarboxylic acid project, with an annual output of 40,000 tons, has steadily increased its market share since its launch in 2022, exemplifying the shift from chemical to bio-based production [6]. - The company's dodecanedioic acid was included in the first batch of the "Iconic Products of Bio-Manufacturing" list published by the Ministry of Industry and Information Technology [6]. Group 3: Innovation and R&D - Kasei Biotech has achieved breakthroughs in several innovative projects, including the production of bio-based piperidine and bio-based continuous fiber composite materials, which are being validated by major clients [6][7]. - The company has filed 39 new invention patents, bringing the total to 516, including 400 invention patents [7]. - The AI protein computing platform has accelerated the efficiency of strain modification, leading to improvements in key technologies such as short-chain dicarboxylic acid strain development [7]. Group 4: Industry Applications and Expansion - Kasei Biotech has established a complete industrial chain from monomers to resins and composite materials, with applications in batteries, photovoltaics, construction, hydrogen storage, wind turbine blades, and high-speed rail flame-retardant flooring [8]. - The company is advancing projects such as the bio-based battery shell manufacturing base in collaboration with CATL, with a planned annual output of 41,000 tons of bio-based composite materials [8]. Group 5: Upcoming Events - The fourth Synthetic Biology and Green Bio-Manufacturing Conference (SynBioCon 2025) will be held from August 20-22 in Ningbo, focusing on AI and bio-manufacturing, green chemicals, new materials, future food, and agriculture [14][15].